International News
| |
|
|
Lunchtime Coffee Reduces Diabetes Risk
 A study from researchers of the University of Sao Paulo in Ribeirao Preto, Brazil has found that drinking coffee at lunchtime reduces the risk of diabetes. More..
|
|
|
Diabetes Risk Increased by Consuming Sugary Drinks Daily
 A new study has found that people who consume sugary drinks every day face a greater risk of diabetes and heart disease.
Scientists have found More..
|
|
|
Diabetes Reduces Brain Power
 New research indicates that diabetic retinopathy could be associated with poorer memory and diminished brain power in people with Type 2 diabetes.
For More..
|
|
|
HbA1c Test Better Diagnostic of Diabetes Risk Over Fasting Glucose
 A new study by researchers at the Johns Hopkins Bloomberg School of Public Health has suggested that measurements of hemoglobin A1c (HbA1c) more accurately More..
|
|
|
Prediabetics Not Taking Adequate Precautions to Prevent Diabetes
 In 2005, almost 30% of the U.S. adult population had prediabetes, but over 90% were unaware of their prediabetes status. Although it is known that diabetes More..
|
|
Recipe of the day - Adai
|
| |
Ingredients
|
Wt.(gm)
|
Measure
|
| |
Rice |
30 |
2 tbsp |
| |
Black gram dal |
15 |
3 tsp |
| |
Red gram dal |
15 |
3 tsp |
| |
Green gram dal |
15 |
3 tsp |
| |
Fenu greek seeds |
12.5 |
2 tsp |
| |
Oil |
15 |
3 - 3/4 tsp |
| |
Salt |
To taste |
|
|
|
Soak rice dals fenugreeks seeds overnight. In the morning grind them coasery. Add all the spices. Spread ladleful of batter on a hot greased tawa (iron pan). Fry on slow fire on both sides. Cook the entire mixture this way.
|
Domestic News
Novo to launch anti-diabetes drug in India by 2010
The Economic Times: December 31, 2008
New Delhi: Danish pharmaceutical company Novo Nordisk plans to launch its anti-diabetes drug Liraglutide in India by 2010. The company claims that the drug, which helps faster control of blood sugar levels, would treat diabetes faster than insulin.
"Liraglutide has recently completed phase-III clinical trials successfully in India and we are planning to launch the drug by 2010 across the globe. We are working out the marketing strategy, which includes pricing of the medicine and promotional details," said a company spokesperson.
Liraglutide is an analog which has revealed better control of blood sugar compared with insulin therapy in diabetes patients. It reduces hypoglycaemia - the sudden lowering of blood sugar levels - by increasing insulin secretion and delaying gastric emptying.
"The medicine will be administered once daily and is expected to work quickly in comparison with insulin. The compound would act directly on betacells without going through the system and hence the speed of its action would increase. At present, there is no other 'once a daily' medicines available in Indian market for diabetes patients. We plan to promote our compound on these lines," said the spokesperson.